Abbott's TactiCath SE Contact Force Ablation Catheter Approved by FDA

January 21, 2019—Abbott announced FDA approval of the company's TactiCath Contact Force ablation catheter, Sensor Enabled (SE), which is designed to help physicians accurately and effectively treat atrial fibrillation. The device integrates with the company's EnSite Precision cardiac mapping system to help physicians develop more precise images of the heart during cardiac ablation procedures.

According to Abbott, TactiCath SE, which is similar to the company's other sensor-enabled mapping and ablation treatment catheters, delivers precise images of the heart overlaid with real-time electrical activity information. The catheter's ergonomic design provides superior reach and maneuverability during cardiac ablation procedures.

Roger Winkle, MD, commented in the announcement, "Cardiac ablation has become a front-line therapy in the fight against conditions like atrial fibrillation in part because of improvements to the technology available today. The Abbott TactiCath SE ablation catheter represents one of those major improvements and offers an incredibly powerful, yet easy to use, combination of advanced technologies to improve ablation procedures."